NexgenRX Inc. (NXG) - Net Assets

Latest as of September 2025: CA$8.29 Million CAD ≈ $6.00 Million USD

Based on the latest financial reports, NexgenRX Inc. (NXG) has net assets worth CA$8.29 Million CAD (≈ $6.00 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$39.20 Million ≈ $28.35 Million USD) and total liabilities (CA$30.91 Million ≈ $22.36 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read NXG total debt and obligations for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CA$8.29 Million
% of Total Assets	21.15%
Annual Growth Rate	N/A
5-Year Change	38.08%
10-Year Change	N/A
Growth Volatility	79.6

NexgenRX Inc. - Net Assets Trend (2013–2024)

This chart illustrates how NexgenRX Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore NexgenRX Inc. assets under control for the complete picture of this company's asset base.

Annual Net Assets for NexgenRX Inc. (2013–2024)

The table below shows the annual net assets of NexgenRX Inc. from 2013 to 2024. For live valuation and market cap data, see NexgenRX Inc. (NXG) market capitalisation.

Year	Net Assets	Change
2024-12-31	CA$7.62 Million ≈ $5.52 Million	-1.18%
2023-12-31	CA$7.71 Million ≈ $5.58 Million	-12.83%
2022-12-31	CA$8.85 Million ≈ $6.40 Million	-8.87%
2021-12-31	CA$9.71 Million ≈ $7.03 Million	+75.90%
2020-12-31	CA$5.52 Million ≈ $3.99 Million	+199.97%
2019-12-31	CA$1.84 Million ≈ $1.33 Million	-5.95%
2018-12-31	CA$1.96 Million ≈ $1.42 Million	-0.25%
2017-12-31	CA$1.96 Million ≈ $1.42 Million	+158.83%
2016-12-31	CA$758.06K ≈ $548.37K	+1003.21%
2015-12-31	CA$-83.93K ≈ $-60.71K	+81.93%
2014-12-31	CA$-464.55K ≈ $-336.05K	-1161.85%
2013-12-31	CA$-36.81K ≈ $-26.63K	--

Equity Component Analysis

This analysis shows how different components contribute to NexgenRX Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1869516700.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	CA$10.05 Million	131.86%
Total Equity	CA$7.62 Million	100.00%

NexgenRX Inc. Competitors by Market Cap

The table below lists competitors of NexgenRX Inc. ranked by their market capitalization.

Company	Market Cap
Genus PLC LSE:GNS	$19.04 Million
Blender Financial Technologies Ltd TA:BLND	$19.05 Million
Epsium Enterprise Limited Ordinary Shares NASDAQ:EPSM	$19.06 Million
CNFinance Holdings Ltd NYSE:CNF	$19.07 Million
Austin Gold Corp NYSE MKT:AUST	$19.03 Million
Medifron DBT Co. Ltd KQ:065650	$19.03 Million
Ozaurum Resources Ltd AU:OZM	$19.03 Million
Cocrystal Pharma Inc NASDAQ:COCP	$19.02 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in NexgenRX Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 7,714,872 to 7,623,961, a change of -90,911 (-1.2%).
Net income of 614,569 contributed positively to equity growth.
Dividend payments of 908,195 reduced retained earnings.
New share issuances of 187,500 increased equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CA$614.57K	+8.06%
Dividends Paid	CA$908.20K	-11.91%
Share Issuances	CA$187.50K	+2.46%
Other Changes	CA$15.21K	+0.2%
Total Change	CA$-	-1.18%

Book Value vs Market Value Analysis

This analysis compares NexgenRX Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.45x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 12.75x to 3.45x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CA$0.03	CA$0.37	x
2018-12-31	CA$0.03	CA$0.37	x
2019-12-31	CA$0.03	CA$0.37	x
2020-12-31	CA$0.08	CA$0.37	x
2021-12-31	CA$0.14	CA$0.37	x
2022-12-31	CA$0.13	CA$0.37	x
2023-12-31	CA$0.11	CA$0.37	x
2024-12-31	CA$0.11	CA$0.37	x

Capital Efficiency Dashboard

This dashboard shows how efficiently NexgenRX Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 8.06%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.73%
• Asset Turnover: 0.54x
• Equity Multiplier: 4.00x
Recent ROE (8.06%) is above the historical average (6.83%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	0.00%	12.39%	3.67x	0.00x	CA$612.23K
2014	0.00%	-11.33%	5.88x	0.00x	CA$-431.16K
2015	0.00%	-4.04%	0.71x	0.00x	CA$-179.93K
2016	77.54%	10.21%	0.70x	10.80x	CA$512.00K
2017	-31.90%	-11.04%	0.59x	4.93x	CA$-822.12K
2018	-35.61%	-9.72%	0.40x	9.21x	CA$-892.58K
2019	-11.30%	-2.18%	0.45x	11.51x	CA$-392.01K
2020	38.32%	19.16%	0.44x	4.57x	CA$1.56 Million
2021	41.37%	33.93%	0.40x	3.03x	CA$3.05 Million
2022	-0.25%	-0.18%	0.50x	2.91x	CA$-907.49K
2023	-4.30%	-2.40%	0.46x	3.91x	CA$-1.10 Million
2024	8.06%	3.73%	0.54x	4.00x	CA$-147.83K

Industry Comparison

This section compares NexgenRX Inc.'s net assets metrics with peer companies in the Health Information Services industry.

Industry Context

Industry: Health Information Services
Average net assets among peers: $496,144
Average return on equity (ROE) among peers: -67.15%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
NexgenRX Inc. (NXG)	CA$8.29 Million	0.00%	3.73x	$19.03 Million
Diagnos Inc (ADK)	$-3.64 Million	0.00%	0.00x	$16.95 Million
Comprehensive Healthcare Systems Inc (CHS)	$-6.43 Million	0.00%	0.00x	$8.96 Million
Carespan Health Inc (CSPN)	$-2.29 Million	0.00%	0.00x	$688.89K
CardioComm Solutions Inc. (EKG)	$-670.32K	0.00%	0.00x	$1.43 Million
Kovo Healthtech Corp (KOVO)	$-299.00K	0.00%	0.00x	$1.77 Million
Kneat.com Inc (KSI)	$11.18 Million	-56.63%	0.31x	$309.65 Million
Newtopia Inc (NEWU)	$4.20 Million	-184.10%	0.88x	$626.69K
Principal Technologies Inc (PTEC)	$452.37K	-298.34%	0.68x	$19.20 Million
Reliq Health Technologies Inc (RHT)	$1.95 Million	-65.24%	0.03x	$30.60 Million

About NexgenRX Inc.

V:NXG Canada Health Information Services

Market Cap

$19.03 Million

CA$26.31 Million CAD

Market Cap Rank

#25175 Global

#994 in Canada

Share Price

CA$0.37

Change (1 day)

+2.78%

52-Week Range

CA$0.28 - CA$0.43

All Time High

CA$0.43